Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 28, 2024Frontiers in HematologyOpen Access

Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma—final results of the AGMT NHL15B study

View Full Paper
Ask AI
Bookmark
Share

Authors

UJUlrich JaegerMedical University of ViennaISIngrid Simonitsch‐KluppMedical University of ViennaPKPatrick KlammerInnsbruck Medical University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jaeger et al. (2024) studied this question.

synapsesocial.com/papers/68e71fefb6db64358769a0dchttps://doi.org/10.3389/frhem.2024.1331008
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System2026
  2. 2Polatuzumab vedotin, venetoclax, and an <scp>anti‐CD20</scp> monoclonal antibody in relapsed/refractory B‐cell <scp>non‐Hodgkin</scp> lymphoma2024 · 5 citations
  3. 3A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study2025
  4. 4Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study2026
  5. 5First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial2024 · 34 citations